Andrew Joseph, STAT

Andrew Joseph

STAT

Boston, MA, United States

Contact Andrew

Discover and connect with journalists and influencers around the world, save time on email research, monitor the news, and more.

Start free trial

Recent:
  • STAT
Past:
  • Boston.com
  • The Boston Globe
  • Scientific American
  • Fox News
  • Mashable
  • Tech Insider
  • mySA
  • Beaumont Enterprise
  • Houston Chronicle

Recent articles by Andrew:

An estimated 115,000 health workers have died from Covid-19

Globally, just two in five health care workers are fully vaccinated against Covid-19, the WHO said Thursday. → Read More

Covid-19 vaccine delivery is going next-level difficult

With half doses, third doses, and kids' doses, the U.S. Covid-19 vaccine rollout is about to get a lot more complicated. → Read More

What will the rollout of Covid-19 vaccine boosters look like?

Health agencies and providers are bracing for the rollout of Covid-19 vaccine boosters. But they must account for an array of unknowns. → Read More

How the risk of side effects could change with Covid-19 vaccine boosters

STAT asked experts what the landscape of adverse events might look like following another dose, and they stressed that they were speculating. → Read More

Study: Vaccination lowers long Covid risk, even when people are infected

The research is among the earliest evidence that immunization reduces the risk of long Covid even when a breakthrough infection occurs. → Read More

WHO wants experts to investigate the origins of Covid and other pathogens

The WHO is looking for experts to help investigate the origins of pathogens — including the new coronavirus. → Read More

Parents can handle finding out newborns' disease risks, study suggests

Can parents handle finding out their newborn is at higher risk of certain diseases? A small study suggests they can. → Read More

FDA grants full approval to Covid-19 vaccine developed by Pfizer

The vaccine, developed in partnership with BioNTech, is the first of the pandemic vaccines to be granted full licensure. → Read More

Why the coronavirus changed over time, and what it means going forward

We can’t predict the next coronavirus variant. But there are some fundamental principles that explain why the virus has morphed as it has. → Read More

What Delta has changed in the Covid pandemic

In some respects, the Delta variant has changed everything in the Covid-19 pandemic. In others, the same rules still apply. → Read More

States will have to decide exactly how to spend opioid settlement money

States are likely to see lump sums of money doled out for years, and they will be left to decide how to spend it under the guideposts. → Read More

CDC to recommend masks indoors for some vaccinated against Covid-19

Federal health officials will recommend Tuesday that even people who’ve had their Covid-19 shots wear masks in indoor settings in some places, a major setback in the progress in the U.S. epidemic. → Read More

Burning questions about Delta and the next phase of the Covid pandemic

Why is Delta such a big deal? What does it mean for the vaccines? Answers to your burning questions about the next phase of the pandemic. → Read More

Rapid sequencing saved a mysteriously ill baby in record time

When an infant presented mysterious symptoms, doctors sequenced his genome — and got answers in under two days. → Read More

Scientists grapple with picking up research they put on hold during Covid

Scientists are taking stock of non-Covid-19 projects that were scuttled or delayed because of months-long lab closures and other changes. → Read More

Third member of FDA expert committee resigns over Alzheimer's decision

Kesselheim wrote that the approval of Biogen’s Aduhelm “was probably the worst drug approval decision in recent U.S. history.” → Read More

More transmissible variant makes vaccinations more crucial, experts say

There is a new coronavirus variant, one with a nasty combination of features that make it even more dangerous than other strains. → Read More

Aduhelm trial participants reflect on their complicated reactions to approval

For those who volunteered as trial participants for a new Alzheimer’s therapy, the divisive approval spurred a complicated brew of emotions. → Read More

A twist in FDA’s Alzheimer’s decision: no limits on which patients can get it

Doctors thought the FDA would limit who could get the new Alzheimer’s drug to certain early-stage patients — but it did no such thing. → Read More

5 questions about the New York Yankees’ Covid-19 infections

How did it happen? Was there a variant involved? And other pressing questions about the Covid-19 outbreak on the New York Yankees. → Read More